|Assessment Status||Rapid review complete|
|Indication||For the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.|
|Rapid review commissioned||01/07/2022|
|Rapid review completed||17/08/2022|
|Rapid review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of upadacitinib compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.|
The HSE has approved reimbursement following confidential price negotiations, December 2022.